EdgeMarket › What Tang Capital Management Llc reported owning
What Tang Capital Management Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
2.0BPositions
51Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| AUPH Aurinia Pharmaceuticals Inc. | 181.2M | 9.2% | 12.2M | 16.65 | +38.6% |
| CELC Celcuity Inc. | 119.8M | 6.1% | 1.1M | 93.53 | +91.8% |
| MIRM Mirum Pharmaceuticals, Inc. | 114.2M | 5.8% | 1.2M | 96.31 | +44.4% |
| LKFT Lakefront Biotherapeutics NV | 113.6M | 5.8% | 3.8M | 28.80 | -9.3% |
| SPY SPDR S&P 500 ETF TRUST | 109.3M | 5.5% | 168.0K | 765.72 | +20.0% |
| KNSA Kiniksa Pharmaceuticals International, plc | 108.8M | 5.5% | 2.3M | 79.03 | +138.0% |
| CAPR CAPRICOR THERAPEUTICS, INC. | 103.4M | 5.2% | 3.4M | 6.29 | -12.3% |
| PTCT PTC THERAPEUTICS, INC. | 102.2M | 5.2% | 1.5M | 69.82 | +42.9% |
| SYRE Spyre Therapeutics, Inc. | 95.4M | 4.8% | 1.9M | 106.49 | +551.3% |
| unmapped CUSIP 483497103 | 92.1M | 4.7% | 4.6M | — | — |
| CMPX Compass Therapeutics, Inc. | 88.8M | 4.5% | 16.8M | 2.40 | -13.7% |
| TARS Tarsus Pharmaceuticals, Inc. | 83.4M | 4.2% | 1.2M | 72.70 | +31.2% |
| IMCR Immunocore Holdings plc | 79.9M | 4.1% | 2.6M | 36.88 | +13.5% |
| ANAB ANAPTYSBIO, INC | 73.8M | 3.7% | 1.3M | 57.74 | +186.6% |
| CORT CORCEPT THERAPEUTICS INC | 60.5M | 3.1% | 1.5M | 122.25 | +73.7% |
| ANIP ANI PHARMACEUTICALS INC | 54.4M | 2.8% | 707.5K | 75.35 | -16.9% |
| INSM INSMED Inc | 42.5M | 2.2% | 260.0K | 125.77 | -2.8% |
| BNTX BioNTech SE | 41.8M | 2.1% | 470.0K | 116.57 | +4.7% |
| VRDN Viridian Therapeutics, Inc.\DE | 35.1M | 1.8% | 1.8M | 24.29 | +33.9% |
| AVIR Atea Pharmaceuticals, Inc. | 25.9M | 1.3% | 4.8M | 5.43 | +55.1% |
| PGEN PRECIGEN, INC. | 24.8M | 1.3% | 6.4M | 7.20 | +124.3% |
| DNTH Dianthus Therapeutics, Inc. /DE/ | 22.2M | 1.1% | 264.7K | 111.10 | +374.4% |
| CMPS COMPASS Pathways plc | 22.1M | 1.1% | 4.0M | 13.33 | +226.7% |
| CBIO CRESCENT BIOPHARMA, INC. | 21.3M | 1.1% | 1.2M | 17.15 | +24.3% |
| STOK Stoke Therapeutics, Inc. | 16.3M | 0.8% | 500.0K | 32.29 | +67.1% |
| VKTX Viking Therapeutics, Inc. | 16.3M | 0.8% | 500.0K | 33.89 | +31.9% |
| IDYA IDEAYA Biosciences, Inc. | 15.0M | 0.8% | 450.0K | 39.67 | +63.1% |
| NUVB Nuvation Bio Inc. | 13.5M | 0.7% | 3.1M | 6.93 | +155.7% |
| PLRX PLIANT THERAPEUTICS, INC. | 7.7M | 0.4% | 6.1M | 1.16 | -19.2% |
| DERM Journey Medical Corp | 7.6M | 0.4% | 1.6M | 7.75 | +9.6% |
| JANX Janux Therapeutics, Inc. | 7.0M | 0.4% | 500.0K | 17.39 | -30.1% |
| BIIB BIOGEN INC. | 6.4M | 0.3% | 35.0K | 216.78 | +56.0% |
| URGN UroGen Pharma Ltd. | 6.3M | 0.3% | 350.0K | 46.86 | +142.7% |
| ARVN ARVINAS, INC. | 5.7M | 0.3% | 538.7K | 9.37 | +31.9% |
| PMVP PMV Pharmaceuticals, Inc. | 5.3M | 0.3% | 4.2M | 1.33 | -10.1% |
| MRNA Moderna, Inc. | 5.1M | 0.3% | 100.0K | 145.13 | +439.7% |
| HRTX HERON THERAPEUTICS, INC. /DE/ | 5.0M | 0.3% | 6.2M | 0.32 | -75.5% |
| unmapped CUSIP 49372L209 | 4.9M | 0.3% | 664.3K | — | — |
| WVE Wave Life Sciences, Inc. | 4.3M | 0.2% | 600.0K | 5.29 | -44.0% |
| LENZ LENZ Therapeutics, Inc. | 4.1M | 0.2% | 451.1K | 4.68 | -87.9% |
| AGIO AGIOS PHARMACEUTICALS, INC. | 3.4M | 0.2% | 100.0K | 33.09 | -10.1% |
| ERAS Erasca, Inc. | 3.2M | 0.2% | 200.0K | 17.63 | +1107.5% |
| CHRS Coherus Oncology, Inc. | 3.2M | 0.2% | 1.9M | 1.42 | +32.7% |
| NKTX Nkarta, Inc. | 3.1M | 0.2% | 1.5M | 2.66 | +17.7% |
| ALT Altimmune, Inc. | 2.1M | 0.1% | 666.0K | 3.11 | -14.3% |
| EOLS Evolus, Inc. | 2.0M | 0.1% | 483.0K | 8.39 | +16.0% |
| ABEO ABEONA THERAPEUTICS INC. | 1.8M | 0.1% | 400.0K | 6.09 | -13.0% |
| FATE FATE THERAPEUTICS INC | 1.4M | 0.1% | 1.2M | 2.33 | +106.2% |
| NMRA Neumora Therapeutics, Inc. | 857.8K | 0.0% | 439.9K | 1.63 | +1.2% |
| LXRX LEXICON PHARMACEUTICALS, INC. | 623.5K | 0.0% | 399.7K | 2.30 | +103.5% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →